Repare Therapeutics Inc
RPTX1.710USD
-0.055-3.12%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
73.46MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Repare Therapeutics Inc Unternehmen
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Unternehmensinformationen
BörsenkürzelRPTX
Name des UnternehmensRepare Therapeutics Inc
IPO-datumJun 19, 2020
CEOMr. Steve Forte
Anzahl der mitarbeiter129
WertpapierartOrdinary Share
GeschäftsjahresendeJun 19
Addresse7210 Frederick-Banting, Suite 100
StadtST-LAURENT
BörseNASDAQ Global Select Consolidated
LandCanada
PostleitzahlH4S 2A1
Telefon18574127018
Websitehttps://www.reparerx.com/
BörsenkürzelRPTX
IPO-datumJun 19, 2020
CEOMr. Steve Forte
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
24.05%
Blue Owl Capital Holdings LP
8.02%
OrbiMed Advisors, LLC
7.73%
Versant Ventures
6.16%
Redmile Group, LLC
3.69%
Andere
50.34%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
24.05%
Blue Owl Capital Holdings LP
8.02%
OrbiMed Advisors, LLC
7.73%
Versant Ventures
6.16%
Redmile Group, LLC
3.69%
Andere
50.34%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
29.96%
Investment Advisor/Hedge Fund
11.48%
Investment Advisor
9.09%
Private Equity
7.82%
Venture Capital
6.26%
Individual Investor
1.41%
Research Firm
0.22%
Family Office
0.09%
Andere
33.67%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
2023Q1
213
37.90M
90.09%
-4.89M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
10.33M
24.09%
--
--
Apr 15, 2025
Blue Owl Capital Holdings LP
3.37M
7.86%
-71.16K
-2.07%
Apr 15, 2025
OrbiMed Advisors, LLC
3.20M
7.46%
-122.13K
-3.68%
Apr 15, 2025
Versant Ventures
2.97M
6.92%
+321.00K
+12.13%
Apr 15, 2025
Redmile Group, LLC
1.88M
4.39%
-31.70K
-1.65%
Mar 31, 2025
MPM Capital Inc.
1.12M
2.61%
-819.92K
-42.24%
Mar 31, 2025
Citadel Advisors LLC
937.49K
2.19%
+937.49K
--
Mar 31, 2025
MPM BioImpact LLC
819.92K
1.91%
-411.23K
-33.40%
Mar 31, 2025
Acadian Asset Management LLC
640.33K
1.49%
+168.23K
+35.63%
Mar 31, 2025
Renaissance Technologies LLC
298.66K
0.7%
-48.80K
-14.04%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
